Female pattern hair loss (female androgenetic alopecia)
Exam Tips
- Classic OSCE stem: gradual central scalp thinning + widened parting + preserved frontal hairline = FPHL until proven otherwise.
- If hair loss is abrupt or heavy shedding predominates, think telogen effluvium rather than FPHL.
- Scarring, perifollicular scale/erythema, pustules, or eyebrow loss should trigger concern for scarring alopecia/frontal fibrosing alopecia and urgent dermatology referral.
- Always ask targeted endocrine questions (cycle irregularity, hirsutism, acne, infertility) to identify women needing androgen work-up.
- Counselling point frequently tested: visible improvement takes months and reverses after treatment cessation.
Definition
Female pattern hair loss (FPHL), also called female androgenetic alopecia, is a chronic non-scarring alopecia characterized by progressive reduction in terminal hair density over the central scalp. It usually presents with widening of the midline parting and diffuse thinning over the crown/frontal scalp while the frontal hairline is relatively preserved.
Pathophysiology
FPHL is a polygenic, multifactorial disorder of follicular cycling in genetically susceptible women. Over repeated cycles, susceptible follicles undergo progressive miniaturization: anagen (growth phase) shortens, telogen proportion rises, and terminal pigmented hairs are replaced by shorter, finer vellus-like hairs, reducing visible density. Androgen signalling (especially via local conversion of testosterone to dihydrotestosterone by 5-alpha-reductase) contributes in some women, but unlike male pattern baldness, many affected women have normal circulating androgens and no overt hyperandrogenism; altered follicular sensitivity and local enzyme activity are likely important. Oestrogen-androgen balance and environmental modifiers (for example smoking, stress, UV exposure) may influence progression.
Risk Factors
- Increasing age (prevalence rises after menopause)
- Family history in first-degree relatives (maternal or paternal side)
- White/Caucasian ethnicity (lower reported prevalence in East Asian cohorts)
- Genetic predisposition (polygenic inheritance)
- Smoking and chronic psychosocial stress
- Potential endocrine association in a subset (for example PCOS-related hyperandrogenism)
Clinical Features
Symptoms
- Gradual hair thinning rather than sudden clumps of shedding
- Perceived reduced ponytail volume and widening central parting
- Cosmetic distress, low mood, anxiety, reduced self-esteem
- Usually no scalp pain; mild increased shedding can occur
Signs
- Diffuse reduced density over crown and frontal scalp with preserved frontal hairline
- Widened midline parting (Ludwig pattern; Olsen 'Christmas-tree' variant possible)
- Occipital hair relatively spared
- No scarring, no marked scale, pustules, or scalp inflammation in typical disease
- Assess for hyperandrogenism signs: hirsutism, severe acne, seborrhoea, menstrual disturbance
- See Figure: Ludwig scale (Stages I-III) for exam pattern recognition
Investigations
Management
Lifestyle Modifications
- Provide realistic counselling: response is slow (typically 3-6 months), treatment must be continued long term to maintain benefit
- Optimize hair care (avoid traction hairstyles, harsh chemical/heat damage) and camouflage options if desired
- Screen and support psychological impact; consider anxiety/depression assessment when distress is significant
- Address contributory factors (iron deficiency, thyroid disease, crash dieting, smoking)
Pharmacological Treatment
Topical vasodilator/hair-growth stimulant
- Minoxidil scalp solution 2% or 5%: apply 1 mL to affected scalp twice daily (maximum 2 mL/day)
- Minoxidil 5% foam: typically 1 g (about half a capful) once daily in women
First-line medical treatment in UK practice. Warn about initial shedding in first weeks, local irritation/contact dermatitis, and unwanted facial hypertrichosis. Benefit is lost within months of stopping. Avoid use on inflamed/broken scalp; caution/avoid in pregnancy and breastfeeding unless specialist advice. Rare systemic effects include hypotension, tachycardia, dizziness.
Anti-androgen therapy (specialist/off-label in selected women)
- Spironolactone 50-200 mg once daily (titrated)
- Finasteride 2.5-5 mg once daily (postmenopausal women only, specialist use)
Not routine first-line in primary care for typical FPHL. Requires specialist selection and monitoring. Finasteride is teratogenic to a male fetus and contraindicated in pregnancy; reliable contraception is essential if of childbearing potential. Spironolactone can cause hyperkalaemia, menstrual irregularity, breast tenderness, and hypotension; monitor renal function and potassium.
Surgical / Interventional
- Hair transplantation (follicular unit transplantation/extraction) in carefully selected, stable disease
- Adjunctive cosmetic procedures (for example scalp micropigmentation) via specialist services
Complications
- Psychological morbidity: reduced self-esteem, social withdrawal, anxiety, and depressive symptoms
- Chronic progression with worsening cosmetic burden
- Treatment-related adverse effects (for example irritant dermatitis or hypertrichosis with minoxidil)
Prognosis
FPHL is usually slowly progressive but variable and difficult to predict in an individual patient. Complete baldness is uncommon in women because miniaturization is typically less profound and more heterogeneous than in men. Earlier treatment and shorter disease duration tend to correlate with better visible response, but maintenance therapy is usually required; stopping treatment often leads to renewed thinning within 3-6 months.
Sources & References
✅NICE Guidelines(1)
📖Textbook References(2)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1221, 1222)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1684)[context]